Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 14/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743937 | 0.91 | POLB (0.42) | GPR139NPC1ALDH1A1TP53RAB9A | |
| SCHEMBL7074092 | 0.89 | MAPK1 (0.46) | MAPK1GRM5 | |
| SCHEMBL7079757 | 0.85 | KMT2A (0.46) | GRM5NPC1ALDH1A1TP53RAB9A | |
| SCHEMBL7743960 | 0.83 | KMT2A (0.44) | MAPK1GRM5NPC1ALDH1A1TP53 | |
| SCHEMBL7743318 | 0.83 | MEN1 (0.41) | MAPK1GPR139NPC1ALDH1A1TP53 | |
| SCHEMBL7712132 | 0.83 | CYP2C9 (0.42) | GRM5NPC1ALDH1A1TP53RAB9A | |
| SCHEMBL6816543 | 0.83 | CYP2C9 (0.42) | GRM5NPC1ALDH1A1TP53RAB9A | |
| SCHEMBL7078783 | 0.83 | RAB9A (0.40) | MAPK1GRM5NPC1ALDH1A1TP53 | |
| SCHEMBL7075380 | 0.83 | CYP2C9 (0.49) | KCNQ3KCNQ2KCNE1KCNQ1NPC1 | |
| SCHEMBL7743904 | 0.82 | ALDH1A1 (0.46) | GRM5NPC1ALDH1A1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140913-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | claimed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | claimed |
| WO-2000034269-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| US-6555561-B2 | N-(5-((((5-Chloro-2,4-dimethoxyphenyl)amino)thioxomethyl)-amino)-2 -pyridinyl)-2-methylbenzamide, for example; inhibiting replication of a herpes virus | WYETH | 2003-04-29 | — | — | US | disclosed |
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-6407123-B1 | VIRICIDES FOR TREATMENT OF HUMAN CYTOMEGALO, EPSTEIN-BARR, VARICELLA-ZOSTER AND KAPOSI*S HERPES VIRAL INFECTIONS | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-18 | — | — | US | disclosed |
| US-6403617-B1 | INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMANHERPESVIRUSES-6 AND -7, AND KAPOSI HERPESVIRUS | AMERICAN HOME PRODUCTS CORP. | 2002-06-11 | — | — | US | disclosed |
| EP-1140913-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6271236-B1 | PHENYL UREAS/THIOUREAS AS INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE ENZYME, USEFUL IN TREATING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, AND VARICELLA-ZOSTER VIRUS | WYETH | 2001-08-07 | — | — | US | disclosed |
| US-6262082-B1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | WYETH | 2001-07-17 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034269-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | HAVCR2, CCR6, CXCR6 | MAPK1 2327/4885GPR139 979/4885GRM5 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.